Kyowa Kirin Co., Ltd. (4151) Press Release
Appendix to the Consolidated Financial Summary (IFRS) Fiscal 2026 Semi Annual
Earlier from Kyowa Kirin
- European Commission Approves Crysvita® (burosumab) for Infants with X-linked Hypophosphataemia in the European Union
- FDA Selects Kyowa Kirin for PreCheck Pilot Program to Accelerate Manufacturing Timelines and Enhance Supply Chain Resilience
- New PROSPER Data Demonstrate Real-World Impact of Mogamulizumab on Symptoms and Health-Related Quality of Life in Mycosis Fungoides and Sézary Syndrome
- Kyowa Kirin to Present New Complementary Evidence Further Defining Clinical Utility of Mogamulizumab in Cutaneous T-Cell Lymphoma at 2026 WCCL